Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 168,414	$ 181,568
Short-term investments	240,157	281,589
Restricted cash (SRX Cardio)	47	173
Trade and other receivables, net	1,693	3,750
Unbilled - collaboration and license revenue	4,660
Inventory	3,248	1,099
Prepaid research and development	3,449	734
Prepaid expenses and other current assets	14,569	9,010
Total current assets	436,237	477,923
Property and equipment, net	5,393	5,217
Intangible assets	7,710	7,851
Long-term investments	42,514	71,076
Prepaid and other long-term assets	4,812	9,609
Total assets	496,666	571,676
Current liabilities:
Accounts payable	20,788	9,304
Accrued compensation and employee benefits	5,113	11,526
Accrued research and development	22,105	44,973
Accrued and other liabilities	5,641	3,552
Deferred revenue, current portion	3,861	11,169
Total current liabilities	57,508	80,524
Notes payable, long-term	51,370	50,565
Long term debt	56,027	54,251
Long term obligation to collaborator	8,000	8,000
Deferred revenue, long-term	5,412	18,798
Other long-term liabilities	8,181	10,045
Total liabilities	186,498	222,183
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized at March 31, 2018 and December 31, 2017; 65,811,082 shares and 65,296,643 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	67	66
Additional paid-in capital	1,568,386	1,551,728
Accumulated deficit	(1,259,660)	(1,204,519)
Accumulated other comprehensive loss	(801)	(409)
Total Portola stockholders’ equity	307,992	346,866
Noncontrolling interest (SRX Cardio)	2,176	2,627
Total stockholders’ equity	310,168	349,493
Total liabilities and stockholders’ equity	$ 496,666	$ 571,676